Characterization of a Novel Humanized Anti-CD20 Antibody with Potent Anti-Tumor Activity against Non-Hodgkin's Lymphoma

Characterization of a Novel Humanized Anti-CD20 Antibody with Potent Anti-Tumor Activity against Non-Hodgkin's Lymphoma

Background: Rituximab, a mouse Fab and human Fc chimeric antibody, has been widely used to treat Non-Hodgkin's lymphoma (NHL). However, only 48% of patients respond to the treatment and complete response rate is below 10%. Also, immunogenicity was reported in 17-20% patients receiving the treat...

Full description

Bibliographic Details
Main Authors: Haifeng Zhang, Liping Song, Hongtu Ye, Lide Hu, Wenlu Liang, Datao Liu
Format: Article
Language:English
Published: Cell Physiol Biochem Press GmbH & Co KG 2013-09-01
Series:Cellular Physiology and Biochemistry
Subjects:
Immunogenicity
Humanization
Anti-CD20 antibody
Non-Hodgkin’s lymphoma
Online Access:http://www.karger.com/Article/FullText/354468

Similar Items

Similar Items